Clinical trial NCT03427073: A Phase I Dose-escalation Study of Subcutaneous ALM201 in Patients With Advanced Ovarian Cancer and Other Solid Tumours
Official title: A Phase I Open-label Multicentre Dose-escalation Study of Subcutaneous ALM201 in Patients With Advanced Ovarian Cancer and Other Solid Tumours
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Solid Tumors
Ovarian Cancer
Lead sponsor: Almac Discovery
Sponsor class: INDUSTRY
First posted: 2018-02-09
Enrollment: 20
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: ALM201/0001 is a Phase I, open-label, dose-escalation study of the safety, tolerability and pharmacokinetics (PK) of ALM201.

Part 1 will be a dose-escalation study. Patients with advanced solid tumours will receive daily doses of ALM201 on Days 1-5, 8-12 and 15-19 in 21 day cycles.

Part 2 will be a dose-expansion of the Maximum Tolerated Dose (MTD) determined in Part 1. Patients with advanced ovarian cancer will be enrolled with the main objective to determine the recommended Phase II dose.

Detailed description: ALM201 is a peptide with anti-angiogenic activity in a range of in-vitro and ex-vivo models. ALM201/0001 is a Phase I, multicentre, open-label, dose-escalation study of the safety, tolerability and pharmacokinetics (PK) of ALM201. The study is divided into two parts.

Part 1 will enrol patients with advanced solid tumours. Patients will receive subcutaneous injection of ALM201 on Days 1-5, 8-12 and 15-19 in 21 day cycles. Patients can receive up to 8 cycles of treatment. Enrolment will follow an accelerated dose-escalation schedule until grade 2 drug-related adverse events are observed, at this point the 3+3 enrolment design will be used. There will be at least 1 week stagger between the first and subsequent patients in a new cohort dose. Dose increments will not exceed 100% escalation and will be guided by data generated from previous cycles. The dose and possibly the schedule will be adjusted to determine the Maximum Tolerated Dose (MTD).

Part 2 will enrol patients with advanced ovarian cancer whose tumour has a proangiogenic profile as assessed by an angiogenesis gene signature biomarker. Patients will receive ALM201 at a dose and schedule established in Part 1.

Patients will undergo safety and tumour assessments as well as blood draws for PK profiling. The safety assessments will involve physical examination, vital signs, biochemistry and haematology laboratory screens as well as immunogenicity testing. Tumour assessments will involve computed tomography (CT) or magnetic resonance imaging (MRI) scans at screening and after every 2 cycles during cycles 1 -8. Patients will be asked to provide consent for access to archived tumour tissue and for fresh biopsies to be taken at pre-dose, tumour response and/or point of disease progression for potential biomarker and pharmacodynamic assessments. PK profiling will be carried out in Cycles 1, 2, 4, 6 and 8.

Eligibility criteria: Inclusion Criteria:

* Part 1 Specific Inclusion Criterion

  \*Patients with histologically and/or cytologically confirmed advanced solid tumour for whom no standard effective therapy is available or felt likely to be of limited efficacy and in whom a rationale for use of an anti-angiogenic treatment approach exists. Note: Previous use of anti-angiogenic therapy is allowed if tolerated
* Part 2 Specific Inclusion Criterion

  \*Patients with advanced ovarian cancer, who are intolerant of or whose tumour is resistant to platinums and who have failed to respond to, or have relapsed following, standard therapy and whose tumour has a proangiogenic profile as assessed by the angiogenesis gene signature test. Note: Previous use of anti-angiogenic therapy is allowed if tolerated.
* General Inclusion Criteria for all Patients

  * Measurable or evaluable disease.
  * Recovery from previous treatment to baseline or CTCAE ≤ Grade 1, as determined by CTCAE v4.03 criteria (Appendix B), of reversible toxicities related to prior treatment, with the exception of alopecia, lymphopenia, other non-clinically significant adverse events; recovery from previous radiotherapy other than residual cutaneous effects or stable \< Grade 2 gastrointestinal toxicity; complete recovery from surgery other than stable \< Grade 2 toxicity.
  * ECOG Performance Status (PS) of 0 or 1.
  * Acceptable haematological, renal and hepatic
  * Women must have either a negative pregnancy test prior to first study drug administration or be post menopausal. Male and female patients of childbearing potential must use appropriate methods birth control.
  * Patients must give written informed consent and understand the requirements of the study

Exclusion Criteria:

For all Patients

* History of inability to tolerate anti-angiogenic therapies e.g. increased blood pressure (BP), proteinuria, prior thromboembolic events.
* Previous history of bowel obstruction, clinical evidence of gastro-intestinal obstruction, large burden of peritoneal disease or evidence of bowel involvement on computed tomography.
* Patents has received:

  * any chemotherapy regimens (including investigational agents) with delayed toxicity within 4 weeks (6 weeks for prior nitrosourea or mitomycin C) of Cycle 1, Day 1, or received chemotherapy regimens given continuously or on a weekly basis which have limited potential for delayed toxicity within 2 weeks of Cycle 1, Day 1.
  * radiotherapy, immunotherapy or biological agents (includes investigational agents) within 4 weeks of Cycle 1, Day 1. Localised palliative radiotherapy is permitted for symptom control.
* Documented, symptomatic or uncontrolled intracranial metastases or primary intracerebral tumours.
* Cancer with leptomeningeal involvement.
* On therapeutic anti-coagulation (aspirin dosing ≤100 mg per oral (PO) daily allowed).
* Previous malignancy, except for non-basal-cell carcinoma of skin or carcinoma-in-situ of the uterine cervix, unless the tumour was treated with curative intent more than 2 years prior to study entry.
* Active cardiac condition or history of significant cardiac condition. Known human immunodeficiency virus positivity.
* Active hepatitis B or C or other active liver disease (other than malignancy).
* Any active, clinically significant, viral, bacterial, or systemic fungal infection within 4 weeks prior to Cycle 1, Day 1.
* Any evidence of severe or uncontrolled systemic conditions or any other issues which make it undesirable for the patient to participate in the study or which could jeopardize compliance with the protocol.

Primary outcomes:
measure: Safety and Tolerability - Evaluation of AEs and DLT
timeFrame: Adverse event evaluation was done during treatment and follow-up. DLT evaluation was done during cycle 1
Secondary outcomes:
measure: Tumour Response Assessment - Best Overall Response
timeFrame: Response assessments were done to assess clinical benefit in the efficacy population overall and at the end of cycles 2, 4 and 6, as applicable
measure: Pharmacokinetics: Tmax
timeFrame: Tmax was determined in cycles 1, 2, 4 and 6 of treatment
measure: Pharmacokinetics: AUC 0-t
timeFrame: AUC 0-t was determined in cycles 1, 2, 4 and 6 of treatment
measure: Pharmacokinetics: Cmax
timeFrame: Cmax of ALM201 following subcutaneous (SC) administration of ALM201 was determined in cycles 1, 2, 4 and 6 of treatment
Other outcomes:
Locations:
city: Belfast
country: United Kingdom
facility: Centre for Cancer Research and Cell Biology, Queen's University Belfast
state: County Antrim
city: Manchester
country: United Kingdom
facility: Dept Medical Oncology, The Christie NHS Foundation Trust
state: Lancashire
city: Newcastle
country: United Kingdom
facility: Freeman Hospital, Northern Centre for Cancer Care, Sir Bobby Robson Cancer Trial research Centre
state: Northumberland
Study officials:
affiliation: Centre for Cancer Research and Cell Biology, Queen's University Belfast
name: Richard Wilson, Professor
role: PRINCIPAL_INVESTIGATOR
References: